Immuneering stock maintained at Outperform by Oppenheimer on survival data
Corroborated by 2 sources from 2 publishers
TL;DR
Reports differ across sources; according to seekingalpha.com, immuneering Corporation (IMRX) Discusses Positive Atebimetinib ASCO Data Update in First-Line Pancreatic Cancer June 1, 2026 8:00 AM EDT Company Participants Courtney Dugan - VP and Head of Investor Relations & Corporate Communications Benjamin Zeskind - Co-Founder, President, CEO & Director Conference Call Participants Douglas Macpherson - Mizuho Securities USA LLC, Research Division Jay Olson - Oppenheimer & Co.
Sources
1
Investing.com News
https://www.investing.com/news/analyst-ratings/immuneering-stock-maintained-at-outperform-by-oppenheimer-on-survival-data-93CH-4719695
2
Seeking Alpha Market News
https://seekingalpha.com/article/4910624-immuneering-corporation-imrx-discusses-positive-atebimetinib-asco-data-update-in-first-line?source=feed_all_articles